| Autor: |
Ming Zheng, MD, PhD, Yutong Sima, MD, Chengyao Liu, MD, PhD, Jinming Zhao, MD, Shan Shao, MD, Xinmao Wang, MD, Yue Wang, MD, Feifei Cao, BS, Wei Xiong, BS, Xiangdong Wang, MD, PhD, Luo Zhang, MD, PhD |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
World Allergy Organization Journal, Vol 15, Iss 10, Pp 100702- (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1939-4551 |
| DOI: |
10.1016/j.waojou.2022.100702 |
| Popis: |
Background: Clinical studies on the effectiveness of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are scarce in China. Moreover, identifying potential biomarkers predicting its efficacy remains a great challenge. Methods: In this prospective trial, all enrolled patients underwent endoscopic examination, computed tomography, blood tests, etc, and they completed a 22-item sino-nasal outcome test (SNOT-22), visual analogue scale (VAS), and asthma control test (ACT) evaluation, at baseline and after 24-week omalizumab therapy. Results: Twenty-two patients were finally recruited. Their VAS scores were significantly better including nasal congestion, anterior rhinorrhea, postnasal drip, and loss of smell (P 20. The median change in the Lund-MacKay score (LMS) was 6. Both the Lund-Kennedy score (LKS) and nasal polyp score showed significant improvement (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
